Substantial impact of coronavirus pandemic on other diagnostic testsChristian Fernsby ▼ | September 24, 2020
The BIVDA Market Audit Report for the first half of 2020 has been published to participants.
Diagnostic tests Thermofisher Scientific
Twenty seven companies submitted revenue data which has been consolidated into a detailed report on the market size and growth, from totals down to assay level.
For the first time Thermofisher Scientific have submitted data for their Microbiology products, further enhancing the coverage of the market which exceeds 95% of the total IVD market excluding Glucose self-tests.
The results show a substantial impact of the coronavirus pandemic and subsequent ‘lockdown’ period on diagnostic tests performed.
Although the total market grew by 2.5%, revenues from General Chemistry, Hormones and Tumour Marker tests were reduced by 10 to 15% in the period (and this impact reflects only 3 months of ‘lockdown’ from the half year).
Some test revenues were reduced by over 90%, while others increased by as much or more, and revenues from Coronavirus testing became one of the largest categories from negligible levels in 2019. ■